| Product Code: ETC4640009 | Publication Date: Nov 2023 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Orphan Drugs Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Orphan Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Orphan Drugs Market - Industry Life Cycle |
3.4 Greece Orphan Drugs Market - Porter's Five Forces |
3.5 Greece Orphan Drugs Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Greece Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Greece Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2021 & 2031F |
4 Greece Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of rare diseases in Greece |
4.2.2 Favorable government policies and incentives for orphan drug development |
4.2.3 Growing awareness and advocacy for orphan drugs in the healthcare sector |
4.3 Market Restraints |
4.3.1 High costs associated with orphan drug development and production |
4.3.2 Limited patient population for orphan drugs in Greece |
4.3.3 Regulatory challenges and approval process for orphan drugs in the country |
5 Greece Orphan Drugs Market Trends |
6 Greece Orphan Drugs Market Segmentations |
6.1 Greece Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Greece Orphan Drugs Market Revenues & Volume, By Revlimid, 2021-2031F |
6.1.3 Greece Orphan Drugs Market Revenues & Volume, By Rituxan, 2021-2031F |
6.1.4 Greece Orphan Drugs Market Revenues & Volume, By Opdivo, 2021-2031F |
6.1.5 Greece Orphan Drugs Market Revenues & Volume, By Keytruda, 2021-2031F |
6.1.6 Greece Orphan Drugs Market Revenues & Volume, By Imbruvica, 2021-2031F |
6.1.7 Greece Orphan Drugs Market Revenues & Volume, By Soliris, 2021-2031F |
6.2 Greece Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Greece Orphan Drugs Market Revenues & Volume, By Biologics, 2021-2031F |
6.2.3 Greece Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2021-2031F |
6.3 Greece Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 Greece Orphan Drugs Market Revenues & Volume, By Oncology, 2021-2031F |
6.3.3 Greece Orphan Drugs Market Revenues & Volume, By Blood, 2021-2031F |
6.3.4 Greece Orphan Drugs Market Revenues & Volume, By Endocrine, 2021-2031F |
6.3.5 Greece Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2021-2031F |
6.3.6 Greece Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2021-2031F |
6.3.7 Greece Orphan Drugs Market Revenues & Volume, By Respiratory, 2021-2031F |
7 Greece Orphan Drugs Market Import-Export Trade Statistics |
7.1 Greece Orphan Drugs Market Export to Major Countries |
7.2 Greece Orphan Drugs Market Imports from Major Countries |
8 Greece Orphan Drugs Market Key Performance Indicators |
8.1 Number of orphan drug designations and approvals in Greece |
8.2 Percentage of healthcare professionals trained in orphan drug treatment |
8.3 Patient access and reimbursement rates for orphan drugs in the market |
9 Greece Orphan Drugs Market - Opportunity Assessment |
9.1 Greece Orphan Drugs Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Greece Orphan Drugs Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 Greece Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2021 & 2031F |
10 Greece Orphan Drugs Market - Competitive Landscape |
10.1 Greece Orphan Drugs Market Revenue Share, By Companies, 2024 |
10.2 Greece Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here